13.6 C
New York
Saturday, September 24, 2022

-$0.68 EPS Expected for COMPASS Pathways plc (NASDAQ:CMPS) This Quarter



Analysts predict that COMPASS Pathways plc (NASDAQ:CMPSGet Rating) will report ($0.68) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for COMPASS Pathways’ earnings. The highest EPS estimate is ($0.65) and the lowest is ($0.73). COMPASS Pathways reported earnings of ($0.35) per share in the same quarter last year, which indicates a negative year over year growth rate of 94.3%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that COMPASS Pathways will report full-year earnings of ($2.85) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.69). For the next fiscal year, analysts expect that the company will post earnings of ($3.37) per share, with EPS estimates ranging from ($3.69) to ($3.04). Zacks’ EPS calculations are an average based on a survey of research analysts that cover COMPASS Pathways.

COMPASS Pathways (NASDAQ:CMPSGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter in the prior year, the firm posted ($0.52) EPS.

Several equities analysts have issued reports on CMPS shares. Zacks Investment Research lowered COMPASS Pathways from a “hold” rating to a “sell” rating in a report on Tuesday, March 1st. Canaccord Genuity Group dropped their price target on COMPASS Pathways from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Monday, February 28th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $74.89.

In related news, insider Ekaterina Malievskaia sold 6,372 shares of the stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total transaction of $79,522.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Y. Norton sold 3,384 shares of the firm’s stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total transaction of $42,232.32. The disclosure for this sale can be found here.

Several institutional investors and hedge funds have recently bought and sold shares of the company. AGF Investments Inc. grew its holdings in COMPASS Pathways by 937,652.9% during the third quarter. AGF Investments Inc. now owns 637,672 shares of the company’s stock worth $19,047,000 after acquiring an additional 637,604 shares during the period. CQS US LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth $5,945,000. BlackRock Inc. acquired a new position in shares of COMPASS Pathways during the 4th quarter worth $4,781,000. Millennium Management LLC increased its holdings in shares of COMPASS Pathways by 533.0% in the 4th quarter. Millennium Management LLC now owns 96,132 shares of the company’s stock valued at $2,125,000 after purchasing an additional 118,332 shares in the last quarter. Finally, Ghost Tree Capital LLC lifted its stake in shares of COMPASS Pathways by 110.0% in the fourth quarter. Ghost Tree Capital LLC now owns 210,000 shares of the company’s stock valued at $4,641,000 after purchasing an additional 110,000 shares during the period. 17.86% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:CMPS opened at $9.06 on Friday. COMPASS Pathways has a 12 month low of $9.06 and a 12 month high of $49.51. The firm has a market capitalization of $380.70 million, a P/E ratio of -5.09 and a beta of 3.34. The company’s fifty day moving average price is $12.67 and its 200 day moving average price is $21.35.

About COMPASS Pathways (Get Rating)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.

Featured Stories

Get a free copy of the Zacks research report on COMPASS Pathways (CMPS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for COMPASS Pathways Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for COMPASS Pathways and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

Related Articles

Stay Connected

0FansLike
3,495FollowersFollow
0SubscribersSubscribe

Latest Articles